OBJECTIVE This study's objective was to analyze the role of various β-blockers in managing exercise-induced blood pressure escalations, termed as exaggerated BP response (eBPR). Despite the importance of this phenomenon, limited data exists on β-blocker efficacy in controlling eBPR.
METHODS Our retrospective cohort for this study consisted of 2803 individuals who underwent treadmill tests from January 2016 to February 2018. Further subgroup analysis of 1258 patients receiving β-blocker treatment was performed to evaluate the influence of different β-blockers on eBPR.
RESULTS Our results demonstrated that β-blockers indeed play a significant role in mitigating the occurrence of eBPR (p=0.026), irrespective of the specific type of β-blocker. Additionally, no significant variance was noticed in eBPR development among different β-blocker groups (p=0.532 for systolic BP, p=0.068 for diastolic BP). This finding remained consistent even among the 992 hypertensive patients, where no notable association was found between the type of β-blocker and eBPR development (p=0.736 for systolic BP, p=0.349 for diastolic BP). It is noteworthy that patients using β-blockers had unique clinical and demographic attributes.
CONCLUSION Our study suggests that β-blockers can potentially deter eBPR development during physical activity, a benefit that is consistent across all types of β-blockers. The study shed light on prospective-randomized studies on the use of eBPR as a new treatment target.
Copyright © 2023 Archives of the Turkish Society of Cardiology